Popular Weight Loss Drugs Show Promise in Slowing Cancer Spread

Breakthrough Research Reveals Unexpected Benefits

A major new study has uncovered compelling evidence that GLP-1 drugs—the medications behind household names like Ozempic and Wegovy—may significantly reduce the risk of cancer spreading to advanced stages. The research found people with lung cancer who were on GLP-1s were 50% less likely to progress to stage 4 than those taking a DPP-4 inhibitor, while for breast cancer, people taking a GLP-1 were 43% less likely to progress.

The Cleveland Clinic study analyzed health records of 12,112 people with seven different types of cancer, comparing outcomes between patients taking GLP-1 medications and those using DPP-4 inhibitors, another class of diabetes drugs. GLP-1 RA exposure was linked to reduced metastatic progression in six of the seven malignancies studied , with statistically significant improvements in four cancer types.

Among patients diagnosed with non-small cell lung cancer, 22% taking DPP-4 inhibitors progressed to stage IV, compared with only 10% taking GLP-1s. For breast cancer patients, 20% of DPP-4 patients progressed, compared to 10% of GLP-1 patients.

Beyond Weight Loss and Diabetes Control

GLP-1 drugs, like Ozempic, Wegovy, Mounjaro and Zepbound, were initially developed for Type 2 diabetes, but are now commonly associated with weight loss. However, their expanding list of health benefits continues to surprise researchers. Approvals have been expanded to reduce risk of heart disease (Wegovy), to prevent worsening kidney disease (Ozempic) and to treat obstructive sleep apnea (Zepbound).

As Dr. Marcin Chwistek, Chief of Supportive Oncology at Fox Chase Cancer Center, noted: "GLP-1 RAs have never been just glucose-lowering drugs. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects." About 20 million Americans are currently taking GLP-1 receptor agonists , making these potential cancer benefits particularly significant.

Lead researcher Dr. Mark Orland suspects the benefits observed were "likely related to the drug itself," rather than resulting from better controlled diabetes or obesity. The study also found that GLP-1 receptor expression was associated with overall survival, suggesting that GLP-1 signaling could be involved in the progression of these cancers.

Important Limitations and Next Steps

The study was observational, and cannot prove cause and effect. Randomized clinical trials would be needed to prove that GLP-1s could slow cancer progression. The study does not confirm that GLP-1 directly kills any tumor cells, and because the analysis was observational, the results do not fully prove that GLP-1s directly impact progression.

People with diabetes are one to two times more likely to develop certain cancers, such as pancreatic cancer, and these cancers can be linked to high glucose environments and high sugar and inflammatory environments where inflammation can drive the cancer's progression. This connection makes the diabetes-cancer treatment overlap particularly intriguing for researchers.

Looking Ahead

Ongoing research will look at how GLP-1s might be controlling cancer progression: For example, by directly telling cancer cells or the cells that support them to stop growing, by affecting the immune system and how it attacks cancer cells, by reducing inflammation, or by changing how cancer cells get fuel.

The findings, which will be presented at the 2026 American Society of Clinical Oncology annual meeting, represent the largest real-world evidence to date suggesting these widely-used medications may have far-reaching health benefits beyond their original purpose. While more rigorous clinical trials are needed, the consistency of results across multiple cancer types offers hope for millions of patients facing both diabetes and cancer diagnoses simultaneously.